Cure Pharmaceutical Reports Second Quarter 2022 Results With Increased Sequential Revenues and Strong Margins
September 02, 2022 06:00 ET
|
Cure Pharmaceutical Holding Corp.
Balance Sheet and Governance Strengthened with Asset Sale and Board Appointments New Marketing Programs Showing Encouraging Early Results OXNARD, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- CURE...
CURE Pharmaceutical Announces Rob Davidson as new Chairman of the Board and Appointment of Rob Costantino as Member of the Board and Audit Committee Chairman
August 16, 2022 06:00 ET
|
Cure Pharmaceutical Holding Corp.
Rob Davidson brings a deep understanding of CURE pipeline, provides expertise in continued new product development, patent creation and continuity in non-dilutive on-going deal transactions and years...
CURE Pharmaceutical Provided Full Corporate Update on Recent Shareholder Call
August 09, 2022 09:00 ET
|
Cure Pharmaceutical Holding Corp.
OXNARD, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that the Company hosted a...
CURE Pharmaceutical Announces the Appointment of New Board Member
August 02, 2022 09:00 ET
|
Cure Pharmaceutical Holding Corp.
OXNARD, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced the appointment of Gerald Bagg to...
CURE Pharmaceutical Announces Teleconference With Investors
August 01, 2022 09:00 ET
|
Cure Pharmaceutical Holding Corp.
OXNARD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that the Company will be hosting...
CURE Pharmaceutical Announces the Sale of a Portion of its Platform Technology IP for $20 Million
July 28, 2022 09:00 ET
|
Cure Pharmaceutical Holding Corp.
OXNARD, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that it has sold a portion of its...
CURE Pharmaceutical Announces Positive Findings from Study at Cincinnati Children’s Hospital Medical Center (CCHMC) Using CURE’s Proprietary, Oral Thin Film (OTF) High, Single Dose Vitamin D in Pediatric Patients Pre- and Post-Hematopoietic Stem Cell Transplantation (HSCT)
May 12, 2022 13:42 ET
|
Cure Pharmaceutical Holding Corp.
CURE’s Patented and Proprietary OTF Vitamin D Found to be More Effective than Standard Supplementation in Achieving pre- and post-Surgery Vitamin D Sufficiency Necessary to Reduce Immune-Mediated...
Sera Labs Inc. Products Now Available at Walmart, Bed Bath & Beyond, CVS and Target.com
April 14, 2022 08:00 ET
|
Cure Pharmaceutical Holding Corp.
LOS ANGELES, April 14, 2022 (GLOBE NEWSWIRE) -- Sera Labs, a wholly subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced its Seratopical Revolution skincare line will be sold...
CURE Pharmaceutical and Milagro Pharmaceuticals Collaborate for Registration and Approval to Sell Sildenafil Oral Thin Film in Mexico
March 03, 2022 11:18 ET
|
CURE Pharmaceutical Holding Corp.
OXNARD, Calif. and LAS VEGAS, March 03, 2022 (GLOBE NEWSWIRE) -- Cure Pharmaceutical (OTC: CURR) a developer and manufacturer of innovative delivery formulations for drugs, supplements and wellness...
Sera Labs, a Subsidiary of CURE Pharmaceutical, Consummates Exclusive International Distribution Agreement With Leading Canadian Distributor
December 09, 2021 07:30 ET
|
CURE Pharmaceutical Holding Corp.
LOS ANGELES and TORONTO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- The Sera Labs, a wholly owned subsidiary of CURE Pharmaceutical Holdings (OTCQB: CURR) today announced its global expansion into Canada by...